Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with Chronic hepatitis C genotype 1confirmed at screening;~* Anti-HCV positive；~* HCV RNA ≥1 × 10000IU / mL;~* Not treated with interferon and / or any other direct-acting antiviral (DAA) drug;~* Non-cirrhotic;~* Voluntarily sign informed consent.~Exclusion Criteria:~* HCV genotypes 2 to 7 or undetectable HCV genotype or mixed HCV genotype;~* Fibroscan detection result \> 12.9kPa or Histopathological examination result of patients is with cirrhosis;~* Past or existing evidence of the presence of non-HCV-induced chronic liver disease;~* Previous history of hepatocellular carcinoma, or suspected hepatocellular carcinoma found prior to screening, or suspected abdominal hepatoblastoma at screening or AFP\>100ng/mL;~* Anti-HAV (IgM) 、HBsAg 、anti-HEV (IgM) or anti-HIV is positive;~* BMI\<18 or≥30 kg/m2;~* ANC\<1.5×109/L、PLT\<100×109/L、HB\<110g/L（female）or\<120g/L（male）；INR\>1.5；ALT or AST≥5\*ULN；TBIL≥2\*ULN（DBIL≥ 35%TBIL）；Cr≥1.5\*ULN;~* Others as specified in detailed protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): Ravidasvir + Danoprevir + Ritonavir + Ribavirin
- Placebo Group (Type: PLACEBO_COMPARATOR): Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).